Houstonian Chris Hunt and his wife, Ashton, created MedVendor to be a search platform that features up-to-date information for case workers for patients seeking at-home care. Photo via Getty Images

Anyone who has had to Google their way to home health care knows that it’s not the best way to get effective help. That’s where MedVendor comes in.

Houstonian Chris Hunt and his wife, Ashton, created MedVendor to be a search platform that features up-to-date information for caseworkers for case workers for patients seeking at-home care.

At the height of the COVID-19 pandemic, Chris Hunt was at a loss for how to help patients. He had recently taken on a new role in wound care sales. His company would send dressings directly to patients, but finding someone who could apply and change them was a different matter.

“It was an absolute nightmare using [Google] as a resource because you had all of these out-of-date listings. So it was a 50-50 shot whether that company would even be in business… And so it would be one in every seven, one in every eight calls that I would make that I could actually get ahold of somebody that I could talk to about wound care services,” Chris Hunt recalls.

In 2020, the couple began interviewing developers to take their idea to reality. They incorporated as an LLC in 2021.

Chris Hunt calls the platform a home-care equivalent to Angie’s List or Yelp. Though it’s currently designed for users in the medical field, he says that they are working on crafting MedVendor to be used by the general public as well.

Users input the type of service they’re looking for, then can select multiple individual patient needs to further tailor the search. “It'll give you a short list from that of companies that can service those criteria. And once you've been given that list, then you can filter patient zip code as well as patient insurance plan to then whittle that search further and really get to a granular level in terms of what resources that you want to find,” Chris Hunt explains.

The couple says that their Houston location has been both a blessing and a curse for their burgeoning business, which released the MedVendor platform on October 1. Though Chris Hunt says that cutting his business’ teeth in Southeast Texas, with its expansive medical community “proves your worth and holds a ton of weight. There you can go to other markets and really capitalize.”

However, MedVendor doesn’t want to be known just as a Texas company — the Hunts hope to expand far beyond the Houston area to eventually become a household name.

Ashton Hunt, who was also in medical sales before the couple took the leap to pursue MedVendor full-time, is marketing director for the company. She adds that in Q4 of this year, they plan to release a phone app version of the platform, which will make using it even easier for medical teams.

“Ideally, a case manager or social worker, if they're working on a discharge plan for a patient, they can even be bedside with them with their phone to help find some resources to then pass along to the family or the caregiver,” Chris Hunt says.

Ultimately, the goal of the company, the couple says, is to open up possibilities for patients. By providing up-to-date, vetted information, the hope is that MedVendor will not only supply them with the care they need, but educate them in the process.

- YouTubewww.youtube.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston's Ion District to expand with new research and tech space, The Arc

coming soon

Houston's Ion District is set to expand with the addition of a nearly 200,000-square-foot research and technology facility, The Arc at the Ion District.

Rice Real Estate Company and Lincoln Property Company are expected to break ground on the state-of-the-art facility in Q2 2026 with a completion target set for Q1 2028, according to a news release.

Rice University, the new facility's lead tenant, will occupy almost 30,000 square feet of office and lab space in The Arc, which will share a plaza with the Ion and is intended to "extend the district’s success as a hub for innovative ideas and collaboration." Rice research at The Arc will focus on energy, artificial intelligence, data science, robotics and computational engineering, according to the release.

“The Arc will offer Rice the opportunity to deepen its commitment to fostering world-changing innovation by bringing our leading minds and breakthrough discoveries into direct engagement with Houston’s thriving entrepreneurial ecosystem,” Rice President Reginald DesRoches said in the release. “Working side by side with industry experts and actual end users at the Ion District uniquely positions our faculty and students to form partnerships and collaborations that might not be possible elsewhere.”

Developers of the project are targeting LEED Gold certification by incorporating smart building automation and energy-saving features into The Arc's design. Tenants will have the opportunity to lease flexible floor plans ranging from 28,000 to 31,000 square feet with 15-foot-high ceilings. The property will also feature a gym, an amenity lounge, conference and meeting spaces, outdoor plazas, underground parking and on-site retail and dining.

Preleasing has begun for organizations interested in joining Rice in the building.

“The Arc at the Ion District will be more than a building—it will be a catalyst for the partnerships, innovations and discoveries that will define Houston’s future in science and technology,” Ken Jett, president of Rice Real Estate Company, added in the release. “By expanding our urban innovation ecosystem, The Arc will attract leading organizations and talent to Houston, further strengthening our city’s position as a hub for scientific and entrepreneurial progress.”

Intel Corp. and Rice University sign research access agreement

innovation access

Rice University’s Office of Technology Transfer has signed a subscription agreement with California-based Intel Corp., giving the global company access to Rice’s research portfolio and the opportunity to license select patented innovations.

“By partnering with Intel, we are creating opportunities for our research to make a tangible impact in the technology sector,” Patricia Stepp, assistant vice president for technology transfer, said in a news release.

Intel will pay Rice an annual subscription fee to secure the option to evaluate specified Rice-patented technologies, according to the agreement. If Intel chooses to exercise its option rights, it can obtain a license for each selected technology at a fee.

Rice has been a hub for innovation and technology with initiatives like the Rice Biotech Launch Pad, an accelerator focused on expediting the translation of the university’s health and medical technology; RBL LLC, a biotech venture studio in the Texas Medical Center’s Helix Park dedicated to commercializing lifesaving medical technologies from the Launch Pad; and Rice Nexus, an AI-focused "innovation factory" at the Ion.

The university has also inked partnerships with other tech giants in recent months. Rice's OpenStax, a provider of affordable instructional technologies and one of the world’s largest publishers of open educational resources, partnered with Microsoft this summer. Google Public Sector has also teamed up with Rice to launch the Rice AI Venture Accelerator, or RAVA.

“This agreement exemplifies Rice University’s dedication to fostering innovation and accelerating the commercialization of groundbreaking research,” Stepp added in the news release.

Houston team develops low-cost device to treat infants with life-threatening birth defect

infant innovation

A team of engineers and pediatric surgeons led by Rice University’s Rice360 Institute for Global Health Technologies has developed a cost-effective treatment for infants born with gastroschisis, a congenital condition in which intestines and other organs are developed outside of the body.

The condition can be life-threatening in economically disadvantaged regions without access to equipment.

The Rice-developed device, known as SimpleSilo, is “simple, low-cost and locally manufacturable,” according to the university. It consists of a saline bag, oxygen tubing and a commercially available heat sealer, while mimicking the function of commercial silo bags, which are used in high-income countries to protect exposed organs and gently return them into the abdominal cavity gradually.

Generally, a single-use bag can cost between $200 and $300. The alternatives that exist lack structure and require surgical sewing. This is where the SimpleSilo comes in.

“We focused on keeping the design as simple and functional as possible, while still being affordable,” Vanshika Jhonsa said in a news release. “Our hope is that health care providers around the world can adapt the SimpleSilo to their local supplies and specific needs.”

The study was published in the Journal of Pediatric Surgery, and Jhonsa, its first author, also won the 2023 American Pediatric Surgical Association Innovation Award for the project. She is a recent Rice alumna and is currently a medical student at UTHealth Houston.

Bindi Naik-Mathuria, a pediatric surgeon at UTMB Health, served as the corresponding author of the study. Rice undergraduates Shreya Jindal and Shriya Shah, along with Mary Seifu Tirfie, a current Rice360 Global Health Fellow, also worked on the project.

In laboratory tests, the device demonstrated a fluid leakage rate of just 0.02 milliliters per hour, which is comparable to commercial silo bags, and it withstood repeated disinfection while maintaining its structure. In a simulated in vitro test using cow intestines and a mock abdominal wall, SimpleSilo achieved a 50 percent reduction of the intestines into the simulated cavity over three days, also matching the performance of commercial silo bags. The team plans to conduct a formal clinical trial in East Africa.

“Gastroschisis has one of the biggest survival gaps from high-resource settings to low-resource settings, but it doesn’t have to be this way,” Meaghan Bond, lecturer and senior design engineer at Rice360, added in the news release. “We believe the SimpleSilo can help close the survival gap by making treatment accessible and affordable, even in resource-limited settings.”